ArticleEpilepsia2018
Neonatal phenobarbital exposure disrupts GABAergic synaptic maturation in rat CA1 neurons.
Article in Epilepsia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 41 citations in OpenAlex.
- Comparison between Phenobarbitone and Levetiracetam as the initial anticonvulsant in preterm neonatal seizures - a pilot randomized control trial in developing country setup.European journal of pediatrics · 2023Trial
- Short-Term Neurodevelopmental Outcome in Term Neonates Treated with Phenobarbital versus Levetiracetam: A Single-Center Experience.Behavioural neurology · 2019Trial
- Padsevonil suppresses seizures without inducing cell death in neonatal rats.Pharmacological reports : PR · 2024Article
- Cenobamate suppresses seizures without inducing cell death in neonatal rats.Epilepsy & behavior : E&B · 2024Article
- Anti-seizure medication-induced developmental cell death in neonatal rats is unaltered by history of hypoxia.Epilepsy research · 2024Article
- Prenatal Exposure to Antiseizure Medications and Risk of Epilepsy in Children of Mothers With Epilepsy.JAMA network open · 2024Article
- A single exposure to brivaracetam or perampanel does not cause cell death in neonatal rats.Frontiers in pediatrics · 2024Article
- Early life phenobarbital exposure dysregulates the hippocampal transcriptome.Frontiers in pharmacology · 2024Article
- Questions and Controversies in Neonatal Seizures.Children (Basel, Switzerland) · 2023Review
- Genetic Background of Epilepsy and Antiepileptic Treatments.International journal of molecular sciences · 2023Review
- "Fifth-day fits" revisited: A literature review of benign idiopathic neonatal seizures and comparison with KCNQ2- and KCNQ3-associated benign familial epilepsy syndromes.Annals of the Child Neurology Society · 2023Review
- Discontinuing Antiseizure Medications After Acute Symptomatic Neonatal Seizures: The Great Trepidation.Neurology. Clinical practice · 2023Article
- Early Discontinuation of Phenobarbital After Acute Symptomatic Neonatal Seizures in the Term Newborn.Neurology. Clinical practice · 2023Article
- Phenobarbital does not worsen outcomes of neonatal hypoxia on hippocampal LTP on rats.Frontiers in neurology · 2023Article
- Effects of Maternal Use of Antiseizure Medications on Child Development.Neurologic clinics · 2022Review
- Commentary - Early discontinuation of antiseizure medication in neonatal seizures - Proceed with caution.Journal of neonatal-perinatal medicine · 2022Article
- Novel Therapeutics for Neonatal Seizures.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
- Activity- and sleep-dependent regulation of tonic inhibition by Shisa7.Cell reports · 2021Article
- Review
- Cannabinoids: A New Perspective on Epileptogenesis and Seizure Treatment in Early Life in Basic and Clinical Studies.Frontiers in behavioral neuroscience · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
objectivePhenobarbital is the most commonly utilized drug for the treatment of neonatal seizures. The use of phenobarbital continues despite growing evidence that it exerts suboptimal seizure control and is associated with long-term alterations in brain structure, function, and behavior. Alterations following neonatal phenobarbital exposure include acute induction of neuronal apoptosis, disruption of synaptic development in the striatum, and a host of behavioral deficits. These behavioral deficits include those in learning and memory mediated by the hippocampus. However, the synaptic changes caused by acute exposure to phenobarbital that lead to lasting effects on brain function and behavior remain understudied.
methodsPostnatal day (P)7 rat pups were treated with phenobarbital (75 mg/kg) or saline. On P13-14 or P29-37, acute slices were prepared and whole-cell patch-clamp recordings were made from CA1 pyramidal neurons.
resultsAt P14 we found an increase in miniature inhibitory postsynaptic current (mIPSC) frequency in the phenobarbital-exposed as compared to the saline-exposed group. In addition to this change in mIPSC frequency, the phenobarbital group displayed larger bicuculline-sensitive tonic currents, decreased capacitance and membrane time constant, and a surprising persistence of giant depolarizing potentials. At P29+, the frequency of mIPSCs in the saline-exposed group had increased significantly from the frequency at P14, typical of normal synaptic development; at this age the phenobarbital-exposed group displayed a lower mIPSC frequency than did the control group. Spontaneous inhibitory postsynaptic current (sIPSC) frequency was unaffected at either P14 or P29+. SIGNIFICANCE: These neurophysiological alterations following phenobarbital exposure provide a potential mechanism by which acute phenobarbital exposure can have a long-lasting impact on brain development and behavior.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.